These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 8179457)
1. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis. Elliott CG; Hiltunen SJ; Suchyta M; Hull RD; Raskob GE; Pineo GF; Jensen RL; Yeates S; Kitterman N Arch Intern Med; 1994 May; 154(9):999-1004. PubMed ID: 8179457 [TBL] [Abstract][Full Text] [Related]
2. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489 [TBL] [Abstract][Full Text] [Related]
3. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Hull RD; Raskob GE; Brant RF; Pineo GF; Valentine KA Arch Intern Med; 1997 Dec 8-22; 157(22):2562-8. PubMed ID: 9531224 [TBL] [Abstract][Full Text] [Related]
4. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Anand S; Ginsberg JS; Kearon C; Gent M; Hirsh J Arch Intern Med; 1996 Aug 12-26; 156(15):1677-81. PubMed ID: 8694666 [TBL] [Abstract][Full Text] [Related]
5. Different effects of heparin in males and females. Campbell NR; Hull RD; Brant R; Hogan DB; Pineo GF; Raskob GE Clin Invest Med; 1998 Apr; 21(2):71-8. PubMed ID: 9562927 [TBL] [Abstract][Full Text] [Related]
6. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Anand SS; Yusuf S; Pogue J; Ginsberg JS; Hirsh J; Circulation; 2003 Jun; 107(23):2884-8. PubMed ID: 12796128 [TBL] [Abstract][Full Text] [Related]
8. Comparison of a weight-based heparin nomogram with traditional heparin dosing to achieve therapeutic anticoagulation. Shalansky KF; FitzGerald JM; Sunderji R; Traboulay SJ; O'Malley B; McCarron BI; Naiman S Pharmacotherapy; 1996; 16(6):1076-84. PubMed ID: 8947981 [TBL] [Abstract][Full Text] [Related]
9. Computer-assisted dosing of heparin. Management with a pharmacy-based anticoagulation service. Kershaw B; White RH; Mungall D; Van Houten J; Brettfeld S Arch Intern Med; 1994 May; 154(9):1005-11. PubMed ID: 8179443 [TBL] [Abstract][Full Text] [Related]
10. Physician practices in the treatment of pulmonary embolism and deep venous thrombosis. Wheeler AP; Jaquiss RD; Newman JH Arch Intern Med; 1988 Jun; 148(6):1321-5. PubMed ID: 3377615 [TBL] [Abstract][Full Text] [Related]
11. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. Hull RD; Raskob GE; Pineo GF; Green D; Trowbridge AA; Elliott CG; Lerner RG; Hall J; Sparling T; Brettell HR N Engl J Med; 1992 Apr; 326(15):975-82. PubMed ID: 1545850 [TBL] [Abstract][Full Text] [Related]
12. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Prandoni P; Carnovali M; Marchiori A; Arch Intern Med; 2004 May; 164(10):1077-83. PubMed ID: 15159264 [TBL] [Abstract][Full Text] [Related]
13. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?]. Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844 [TBL] [Abstract][Full Text] [Related]
14. Appropriate use of heparin. Empiric vs nomogram-based dosing. Gunnarsson PS; Sawyer WT; Montague D; Williams ML; Dupuis RE; Caiola SM Arch Intern Med; 1995 Mar; 155(5):526-32. PubMed ID: 7864708 [TBL] [Abstract][Full Text] [Related]
15. The successful application of a heparin nomogram in a community hospital. Hollingsworth JA; Rowe BH; Brisebois FJ; Thompson PR; Fabris LM Arch Intern Med; 1995 Oct; 155(19):2095-100. PubMed ID: 7575069 [TBL] [Abstract][Full Text] [Related]
17. Heparin dosage adjustment in patients with deep-vein thrombosis using heparin concentrations rather than activated partial thromboplastin time. Groce JB; Gal P; Douglas JB; Steuterman MC Clin Pharm; 1987 Mar; 6(3):216-22. PubMed ID: 3665377 [TBL] [Abstract][Full Text] [Related]
18. Pathophysiology and treatment of deep-vein thrombosis and pulmonary embolism. Carter BL; Jones ME; Waickman LA Clin Pharm; 1985; 4(3):279-96. PubMed ID: 3891200 [TBL] [Abstract][Full Text] [Related]
19. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring. Hull RD; Pineo GF; Stein P Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652 [TBL] [Abstract][Full Text] [Related]
20. A standard heparin nomogram for the management of heparin therapy. Cruickshank MK; Levine MN; Hirsh J; Roberts R; Siguenza M Arch Intern Med; 1991 Feb; 151(2):333-7. PubMed ID: 1789820 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]